Company intelligence
RxClarity
Expert pharma and biotech agents that remember what changed and keep your intelligence up to date.
About RxClarity
Our mission is to make big-pharma intelligence capability accessible to every life-sciences team. A team that never sleeps. RxClarity builds reliable, always-on AI agents that continuously monitor the market, verify what changed and do the recurring intelligence work — even when your team is offline. Used by biotech, CRO and consulting teams to increase intelligence capacity without increasing headcount at the same pace.
Verified activity
Signals from RxClarity
8 published signals
Research & Knowledge
RxClarity reports that Tezspire advanced towards becoming a potential EoE competitor to Dupixent, while results from Alumis and Spyre narrowed the development paths for two immunology programmes.
Reported by RxClarity
Legal & Regulatory
RxClarity reports that Plozasiran strengthened its competitive position against Tryngolza after reporting a 78% reduction in acute-pancreatitis events and an sNDA planned by year-end.
Reported by RxClarity
Legal & Regulatory
RxClarity reports that LISRAYA became the first FDA-approved oral treatment for adults with dermatomyositis.
Reported by RxClarity
Legal & Regulatory
RxClarity reports that Autoimmune CAR-T faced a significant safety reset as Novartis and Bristol Myers Squibb paused programmes.
Reported by RxClarity
Products & Services
RxClarity is launching a weekly RxClarity roundup covering GI, cardiometabolic and immunology with one approval, two clinical setbacks, and a CAR-T safety reset.
Reported by Zaharan Sofi
Research & Knowledge
RxClarity published the first edition of RxClarity Weekly Signals covering oncology developments across clinical data, regulatory decisions, deals, and pipeline moves.
Reported by RxClarity
Products & Services
RxClarity is posting weekly news summaries categorized by sentiment and type, including approvals, trial milestones, and M&A.
Reported by RxClarity
Products & Services
RxClarity announced weekly signals of news tracking sentiments, type of news, and impact on competitors and the company's positioning.
Reported by Zaharan Sofi